1. Home
  2. BGX vs CRBU Comparison

BGX vs CRBU Comparison

Compare BGX & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Long Short Credit Income Fund

BGX

Blackstone Long Short Credit Income Fund

HOLD

Current Price

$10.73

Market Cap

136.6M

Sector

Finance

ML Signal

HOLD

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

N/A

Current Price

$1.55

Market Cap

145.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BGX
CRBU
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.6M
145.8M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
BGX
CRBU
Price
$10.73
$1.55
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
56.7K
976.0K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.64
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.63
Revenue Next Year
N/A
$10.93
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.38
$1.38
52 Week High
$12.60
$3.53

Technical Indicators

Market Signals
Indicator
BGX
CRBU
Relative Strength Index (RSI) 43.61 42.61
Support Level $10.42 $1.52
Resistance Level $10.75 $1.73
Average True Range (ATR) 0.08 0.08
MACD -0.01 -0.00
Stochastic Oscillator 31.01 10.64

Price Performance

Historical Comparison
BGX
CRBU

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The company's seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Share on Social Networks: